90%Confidence
0Views
FDASource
2026-03-24Date
Summary
New Life Pharma's Class II FDA recall for Semaglutide injection due to sterility assurance issues creates significant patient safety risks for a high-demand diabetes/weight loss medication. This recall could disrupt supply in the competitive GLP-1 agonist market and damage trust in newer pharmaceutical distributors.
Actionable: Watch for potential market share shifts to established semaglutide manufacturers like Novo Nordisk and increased FDA scrutiny of compounding pharmacies.
AI Confidence: 90%
Data Points
firmNew Life Pharma LLC
classificationClass II
statusOngoing
distributionOH
productSemaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now